IL6 and neoplasm: Since high IL-6 induces MDSCs and suppresses anti-tumor immunity, reflected by reduced CD8+ lymphocyte counts, it is possible that eribulin is not sufficiently effective in patients with high IL-6 levels due to a poor tumor immune microenvironment.